BC Innovations | Mar 2, 2018
Product R&D

Sigma for synapses

By focusing on synapse protection instead of aggregate formation, Cognition Therapeutics Inc. has identified a new target for Alzheimer’s disease that it believes can block β amyloid’s toxic effects more efficiently than the standard approaches....
BC Week In Review | Nov 10, 2017
Clinical News

Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

Cognition Therapeutics Inc. (Pittsburgh, Pa.) reported data from the Phase Ib/IIa COG0102 trial in 19 patients with mild to moderate Alzheimer’s disease showing that all 3 doses of CT1812 were well tolerated with no serious...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
BC Week In Review | Jun 16, 2017
Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between patients who received twice-daily 800 mg oral PQ912...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
BC Week In Review | Apr 15, 2013
Company News

Neurogen management update

Neurogen Corp. (NRGN), Branford, Conn.   Business: Drug discovery, Metabolic   Hired: James Krause as VP of biochemistry, formerly professor of neurobiology at Washington University  ...
BioCentury | Mar 19, 2012
Emerging Company Profile

ADx NeuroSciences: A progressive approach

Current Alzheimer's disease diagnostics do not distinguish between different oligomers of tau and beta amyloid , and thus have little prognostic value. ADx NeuroSciences N.V. is developing oligomer-specific biomarkers that it expects not only to diagnose...
BC Week In Review | Jan 4, 2010
Company News

Ligand, Neurogen deal

Ligand completed its previously announced acquisition of Neurogen in a stock deal valued at $8.9 million based on 4.2 million shares issued and Ligand's close of $2.13 on Dec. 23, 2009, the last trading day...
BC Week In Review | Aug 31, 2009
Company News

Ligand, Neurogen deal

Ligand will acquire Neurogen for about 4 million shares for a deal value of about $11 million based on Ligand's close of $2.76 on Aug. 21, the day before the deal was announced. Neurogen shareholders...
BioCentury | Aug 31, 2009

Neurogen chronicles

Neurogen chronicles Neurogen Corp. (NASDAQ:NRGN), which is being acquired by Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for $11 million in stock plus conditional payments worth at least $7 million, has had a long history of early clinical...
Items per page:
1 - 10 of 229